SureTrader Stock Hero Advertisement SureTrader SPDR Advertisement
Home > Boards > US OTC > Miscellaneous >

Rich Pharmaceuticals Inc. (RCHA)

Add RCHA Price Alert      Hide Sticky   Hide Intro
Moderator: No Moderator mick, sunspotter, onthegreen, Imarket13
Search This Board:
Last Post: 5/21/2015 9:36:41 PM - Followers: 164 - Board type: Free - Posts Today: 0

RCHA Patent for Treatment of Hodgkin’s Lymphoma
Under terms of the agreement, Rich Pharmaceuticals, Inc. will obtain complete ownership and all interest in the indication, patents and intellectual property related to treatment of Hodgkin’s Lymphoma, utility patent application number 61998397, entitled COMPOSITIONS AND METHODS OF USE OF PHORBOL ESTERS FOR THE TREATMENT OF HODGKIN’S LYMPHOMA.
RCHA Recent News
Rich Pharmaceuticals Announces Completion of the Manufacture of RP-323 Study Drug in Connection with Obtaining FDA's Final Approval of The Investigational New Drug (IND) Application For The Treatment of Acute Myelocytic Leukemia
BEVERLY HILLS, Calif., Feb. 4, 2015 /PRNewswire/ -- Rich Pharmaceuticals, Inc. (RCHA) ("Rich" or the "Company"), a clinical-stage biotechnology company focused on developing innovative therapies in oncology, announced today that it has competed a GMP clinical batch of RP-323 study drug that was manufactured at the state-of-the-art Wuxi Apptec Biopharmaceutical's facility based in Shanghai, China.  This new batch of RP-323 represents a new second-generation compound with improved product usability and stability.  Rich Pharmaceuticals developed the new formulation and all regulatory required testing methods in 2014 and transferred the proprietary technology successfully to Wuxi Apptec for the GMP production of RP-323.  Currently, the new study drug is in the final examination stage at Wuxi Apptec and is expected to be shipped to clinical sites starting mid-February 2015 for the upcoming planned clinical trials.   
Rich Pharmaceuticals submitted its Investigational New Drug (IND) Application for a Phase 2 multi-center study to evaluate the safety and efficacy of RP-323 in patients with AML and MDS in October 2014.  In connection with the IND, Rich Pharmaceuticals was required to manufacture sufficient quantities of RP-323 under GMP.
"We believe RP-323 has best-in-class potential and holds significant promise for patients suffering from AML and MDS," said Ben Chang, Rich Pharmaceuticals' Chief Executive Officer.  Mr. Chang further stated, "We are especially excited to have a partner in the manufacture of RP-323 of the high caliber of Wuxi Apptec.  We expect to pursue the approval of the IND promptly and to be in clinical studies in the very near term."
About Rich Pharmaceuticals:
Rich Pharmaceuticals, Inc. (RCHA) is a biopharmaceutical company developing a treatment for Acute Myelocytic Leukemia (AML)/white blood cell elevation, Hodgkin's Lymphoma and other blood related diseases.  Rich Pharmaceuticals' goal is to extend refractory patients life expectancy and increase quality of life.  Rich Pharmaceuticals' primary development stage product candidate, RP-323, is being designed to treat blood and cancer related diseases through non-evasive outpatient facilities.  Find out more at
WuXi PharmaTech, Inc. trades on the NYSE in the area of $40.00 per share under the ticker of WX with a $2.8 Billion Market Cap:


Below is the indicated Product Pipeline for RCHA:

Here is a key piece from the news as to how it applies:
"We believe RP-323 has best-in-class potential and holds significant promise for patients suffering from AML and MDS," said Ben Chang, Rich Pharmaceuticals' Chief Executive Officer.  Mr. Chang further stated, "We are especially excited to have a partner in the manufacture of RP-323 of the high caliber of Wuxi Apptec.  We expect to pursue the approval of the IND promptly and to be in clinical studies in the very near term."

Courtesy of Sibware: 
RCHA RP-323:Potential Market=$1 to 2 Billion/Year US.$5 Billion Worldwide. 

Business Overview 

The Company is developing RP-323 (formerly called PD-616) for the treatment of Acute Myelogenous Leukemia (AML), and to cause elevation of white blood cells (WBC) in patients depleted of these elements due to various conditions. 

Clinical Studies in Acute Myelocytic Leukemia 

Based on the known properties of RP-323, it was first administered in a pilot study in China, either alone or in combination with standard drugs, and caused temporary remission of AML in some patients’ refractory to standard therapy. Several patients recovered sufficiently with RP-323 treatment to return to their normal occupations, symptom-free. Interest in these findings led to a Phase I investigator-sponsored trial in 35 patients by a leading oncologist at a leading cancer hospital in New Jersey, the University of Medicine and Dentistry of New Jersey (UMDNJ). 

Market Opportunities 


It is estimated that 40,000 people in the US have AML and an additional 14,000 are diagnosed annually with a yearly death rate of over 10,000. Based on this incidence,the potential market for RP-323 for the treatment of AML is approximately $1 to 2 billion peak sales annually in the US and more than $5 billion worldwide.

RCHA Key DD Posts:
Key RCHA & WX:NYSE Relationship
Respectfully, again, key with the Authorized Shares



Contact Us
9595 Wilshire Boulevard, Ste. 900
Beverly Hills, CA 90045

P: 424.230.7001
F: 424.230.7003



Daily View

Weekly View

3 Month Daily View

  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
Current Price
Bid Ask Day's Range
RCHA News: Securities Registration Statement (s-1) 05/21/2015 02:41:55 PM
RCHA News: Current Report Filing (8-k) 05/12/2015 11:19:23 AM
RCHA News: Current Report Filing (8-k) 04/14/2015 02:56:21 PM
RCHA News: Statement of Changes in Beneficial Ownership (4) 04/08/2015 05:19:33 PM
RCHA News: Current Report Filing (8-k) 04/08/2015 05:15:13 PM
News News Alert: Securities Registration Statement (s-1) 05/21/2015 02:41:55 PM
#7384  Sticky Note $RCHA recent news/filings mick 04/17/15 04:23:21 PM
#6618  Sticky Note "in the face of the massive gains we sunspotter 03/17/15 05:07:01 AM
#7709   $RCHA charts $Pistol Pete$ 05/21/15 09:36:41 PM
#7708   this stock is finished, too many shares. IMO valleyview 05/21/15 09:09:46 PM
#7707   lol yupp wuxi still refuses to comment Kaveli 05/21/15 07:04:50 PM
#7706   i got slammed from .01 down to .001 Kaveli 05/21/15 07:03:29 PM
#7705   LOL that was a good Reedbetweendalines 05/21/15 04:59:53 PM
#7704   Mr. Nail Meet Mr. Coffin onthegreen 05/21/15 03:34:16 PM
#7703   It's never going to end. IMO tiller 05/21/15 02:52:23 PM
#7702   Oh jeeze - here comes another 500 Million shares LeGoose 05/21/15 02:44:37 PM
#7701   Onthegreen..thank you. Oh, I am in pain. Eddie1959 05/21/15 11:41:39 AM
#7700   "I hate to say it but this is sunspotter 05/21/15 11:12:24 AM
#7699   Thanks Ben here comes new 52 week low Axeman 05/21/15 11:04:50 AM
#7698   $RCHA is bottom play now Mick. I am $Pistol Pete$ 05/21/15 11:03:04 AM
#7697   Eddie, IMO...the O/S here has exceed 1.5 Billion onthegreen 05/21/15 10:51:33 AM
#7696   Onthegreen..why do you think a r/s? Eddie1959 05/21/15 10:21:52 AM
#7695   Looks to be ready for another bounce IMO HMONNY 05/21/15 10:17:08 AM
#7694   3's today - New 52 week low. Massive onthegreen 05/21/15 09:46:41 AM
#7693   It's coming up on two months since last PR. tiller 05/21/15 08:32:56 AM
#7692   LOL, Nice Chart. PBM$ appears to be what onthegreen 05/20/15 01:34:34 PM
#7691,uu[900,a]decly[dk][pb200!b300!b400!b50 mick 05/20/15 01:08:27 PM
#7690   yeah. My wrong. AS as in authorised shares. valleyview 05/20/15 11:27:02 AM
#7689   You mean AS not OS, I guess Eltp 05/20/15 10:02:24 AM
#7688   GL ... for me I would be valleyview 05/20/15 09:59:13 AM
#7687   I will buy if it hits .0001 Andrew23 05/19/15 08:55:46 PM
#7686   Nice end of day dumping! I didn't onthegreen 05/19/15 06:13:25 PM
#7685   This P&D followed the predictable slide down to Homebrew 05/18/15 03:02:02 PM
#7684   I'm still waiting on the sidelines for this one. jimmac 05/17/15 08:55:54 AM
#7681   Just need one gd pr. criscros 05/15/15 11:50:34 PM
#7680   Not just Monday... Checkout the accumulation/distribution over the Gravity 05/15/15 09:14:06 PM
#7679   Yea but this will hit .0004 .0003 starkd748 05/15/15 07:04:40 PM
#7678   Whole lotta buying at eod. Monday setting up? criscros 05/15/15 07:04:09 PM
#7677   Lol I wouldnt starkd748 05/15/15 07:03:52 PM
#7676   One more dump/8k and we are at .0003. Axeman 05/15/15 12:29:32 PM
#7674   lol .... I think you will have no valleyview 05/15/15 05:47:20 AM
#7673   Will continue to be on watch for possible entry.. Gravity 05/14/15 08:58:45 PM
#7672   i took great loss with this dumb stock kragdason 05/14/15 05:41:31 PM
#7671   I would guess REVERSE SPLIT in the near Axeman 05/14/15 04:02:39 PM
#7669   If anyone wishes to give their money to sunspotter 05/14/15 01:55:36 PM
#7668   It's smart to do so, I'm on the Eltp 05/14/15 01:42:13 PM
#7667   I'm thinking of averaging down some more but dmbrazilian 05/14/15 01:33:47 PM
#7666   dmbrazilian...Hopefully our boat will get picked up by Eddie1959 05/14/15 12:56:00 PM
#7665   I'm in about the same boat... dmbrazilian 05/14/15 12:35:37 PM
#7664   I bought RCHA at 015. I have Eddie1959 05/14/15 12:06:43 PM
#7663   both - the company is dumping and others ospreyeye 05/14/15 11:29:48 AM
#7662   I wouldn't be surprised if .0003's show up today. valleyview 05/14/15 11:20:34 AM
#7661   Can you tell if that was somebody loading Maybeismaybenot 05/14/15 09:49:27 AM
#7660   I agree! tiller 05/14/15 03:39:26 AM
#7659   R/S is the only way it will stay onthegreen 05/13/15 09:54:08 PM
#7658   Won't matter. Ben is dealing with criminals. Go Axeman 05/13/15 08:31:22 PM
#7657   According to the financiers they don't want the ospreyeye 05/13/15 08:19:20 PM
#7656   They must be loading up for something - ospreyeye 05/13/15 08:18:21 PM